Lavipharm S.A. (FRA:BXA0)

Market Cap	247.97M +83.7%
Revenue (ttm)	70.32M +28.6%
Net Income	5.74M +48.6%
EPS	0.03 +43.3%
Shares Out	n/a
PE Ratio	41.60
Forward PE	n/a
Dividend	0.02 (1.46%)
Ex-Dividend Date	Jul 20, 2026

Volume	1,000
Open	1.360
Previous Close	1.402
Day's Range	1.360 - 1.398
52-Week Range	0.706 - 1.850
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 306
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BXA0

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.36%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error